Loading
A phase 2 trial of Alectinib, Entrectinib, Vemurafenib in non-small-cell lung cancer and small-cell lung cancer, run by Genentech, Inc., now recruiting.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT04302025 by Genentech, Inc., with 99 participants planned, started 2020-11-06 and due to reach its primary completion in 2026-11-30. Interventions recorded: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Alectinib, Entrectinib, Roche / Genentech, Small-cell lung cancer.
Shares Alectinib, Atezolizumab, Roche / Genentech, Small-cell lung cancer.
Shares Atezolizumab, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
Shares Cobimetinib, Vemurafenib, Alectinib, Entrectinib.
Shares Resectable stage I to III non-small-cell lung cancer, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cobimetinib, Atezolizumab, Roche / Genentech.
Shares Cobimetinib, Vemurafenib.